Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 50, 2010, Pages 21824-21829

  Fasano, Stefania ^a,b   Bezard, Erwan ^c,d   D'Antoni, Angela ^b   Francardo, Veronica ^a   Indrigo, Marzia ^b   Qin, Li ^d   Doveró, Sandra ^c   Cerovic, Milica ^e   Cenci, M Angela ^a   Brambilla, Riccardo ^b,e  

^a LUND UNIVERSITY   (Sweden)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^d INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LENTIVIRUS VECTOR; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DYSKINESIA; INHIBITION KINETICS; INTRACELLULAR SIGNALING; INVOLUNTARY MOVEMENT; LEVODOPA INDUCED DYSKINESIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THERAPY EFFECT;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LEVODOPA; MICE; MICE, KNOCKOUT; NEURONS; RAS-GRF1; SIGNAL TRANSDUCTION;

MUS; PRIMATES; RODENTIA;

EID: 78650753240     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1012071107     Document Type: Article

References (47)

1. Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9:665-677.
2. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236-243.
3. Calabresi P, Di Filippo M, Ghiglieri V, Picconi B (2008) Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 23(Suppl 3):S570-S579.
4. Cenci MA, Lundblad M (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99:381-392.
5. Orban PC, Chapman PF, Brambilla R (1999) Is the Ras-MAPK signalling pathway necessary for long-term memory formation? Trends Neurosci 22:38-44.
6. Fasano S, Brambilla R (2002) Cellular mechanisms of striatum-dependent behavioral plasticity and drug addiction. Curr Mol Med 2:649-665.
7. Brambilla R (2003) Targeting Ras/ERK signaling in the striatum: Will it help? Mol Psychiatry 8:366-368.
8. Girault JA, Valjent E, Caboche J, Hervé D (2007) ERK2: A logical and gate critical for drug-induced plasticity? Curr Opin Pharmacol 7:77-85.
9. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62:800-810.
10. Santini E, et al. (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27:6995-7005.
11. Pavón N, Martín AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59:64-74.
12. Schuster S, et al. (2008) The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci 28:4311-4316.
13. Sweatt JD (2001) The neuronal MAP kinase cascade: A biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 76:1-10.
14. Davis S, Laroche S (2006) Mitogen-activated protein kinase/extracellular regulated kinase signalling and memory stabilization: A review. Genes Brain Behav 5(Suppl 2): 61-72.
15. Ramos JW (2008) The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 40:2707-2719.
16. Cagnol S, Chambard JC (2010) ERK and cell death: Mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 277:2-21.
17. Kim EK, Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802:396-405.
18. Fasano S, et al. (2009) Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) controls activation of extracellular signal-regulated kinase (ERK) signaling in the striatum and long-term behavioral responses to cocaine. Biol Psychiatry 66(8):758-768.
19. Brambilla R, et al. (1997) A role for the Ras signalling pathway in synaptic transmission and long-term memory. Nature 390:281-286.
20. Lundblad M, et al. (2005) Pharmacological validation of a mouse model of l-DOPAinduced dyskinesia. Exp Neurol 194:66-75.
21. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66:603-613.
22. Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110-123.
23. Valjent E, et al. (2000) Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J Neurosci 20:8701-8709.
24. Santini E, et al. (2009) L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108:621-633.
25. Konradi C, et al. (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 17:219-236.
26. Valastro B, et al. (2007) Proteomic analysis of striatal proteins in the rat model of LDOPA- induced dyskinesia. J Neurochem 102:1395-1409.
27. Crittenden JR, et al. (2009) Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc Natl Acad Sci USA 106:2892-2896.
28. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L (2005) Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 23:108-116.
29. Indrigo M, Papale A, Orellana D, Brambilla R (2010) Lentiviral vectors to study the differential function of ERK1 and ERK2 MAP kinases. Methods Mol Biol 661:205-220.
30. Krapivinsky G, et al. (2003) The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron 40:775-784.
31. Vanoni M, et al. (1999) Characterization and properties of dominant-negative mutants of the ras-specific guanine nucleotide exchange factor CDC25(Mm). J Biol Chem 274:36656-36662.
32. Vantaggiato C, et al. (2006) ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 5:14.1-14.15.
33. Stocchi F, Tagliati M, Olanow CW (2008) Treatment of levodopa-induced motor complications. Mov Disord 23(Suppl 3):S599-S612.
34. Buck K, Ferger B (2010) L-DOPA-induced dyskinesia in Parkinson's disease: A drug discovery perspective. Drug Discov Today 15(19-20):867-875.
35. Bateup HS, et al. (2010) Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci USA 107:14845-14850.
36. Ahmed MR, et al. (2010) Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med 2(28):28ra28.
37. Cenci MA, Konradi C (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183:209-233.
38. Isacson O, Kordower JH (2008) Future of cell and gene therapies for Parkinson's disease. Ann Neurol 64(Suppl 2):S122-S138.
39. Lundberg C, et al. (2008) Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 8:461-473.
40. Nanou A, Azzouz M (2009) Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 175:187-200.
41. Ramaswamy S, Soderstrom KE, Kordower JH (2009) Trophic factors therapy in Parkinson's disease. Prog Brain Res 175:201-216.
42. Andersson M, Konradi C, Cenci MA (2001) cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21:9930-9943.
43. Berton O, et al. (2009) Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry 66:554-561.
44. Bézard E, et al. (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9:762-767.
45. Gold SJ, et al. (2007) RGS9-2 negatively modulates L-3,4- dihydroxyphenylalanineinduced dyskinesia in experimental Parkinson's disease. J Neurosci 27:14338-14348.
46. Boraud T, Bezard E, Bioulac B, Gross CE (2001) Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124:546-557.
47. Guigoni C, et al. (2005) Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 22: 283-287.